COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS ERLOTINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR) NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

Santoni N. B.; Melo T. G.; Aguirre A. R.; Veiga D. L.; Souza C. P.

首页> 外文期刊>Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research >COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS ERLOTINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR) NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

【24h】

COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS ERLOTINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR) NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

机译：AFATINIB对欧洲毒素的成本效果分析作为局部晚期或转移性表皮生长因子受体突变（EGFR）非小细胞肺癌在巴西私人医疗系统中的第一线治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research》 |2017年第5期|共1页
作者
Santoni N. B.; Melo T. G.; Aguirre A. R.; Veiga D. L.; Souza C. P.;
展开▼
作者单位

Boehringer Ingelheim GmbH &

Co KG Sao Paulo Brazil;

Boehringer Ingelheim GmbH &

Co KG Sao Paulo Brazil;

Boehringer Ingelheim GmbH &

Co KG Sao Paulo Brazil;

Boehringer Ingelheim GmbH &

Co KG Sao Paulo Brazil;

Sense Co Rio De Janeiro Brazil;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类预防医学、卫生学;
关键词

相似文献

外文文献
中文文献
专利

1. COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS ERLOTINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR) NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM [J] . Santoni N. B., Melo T. G., Aguirre A. R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：AFATINIB对欧洲毒素的成本效果分析作为局部晚期或转移性表皮生长因子受体突变（EGFR）非小细胞肺癌在巴西私人医疗系统中的第一线治疗
2. COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS GEFITINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM [J] . Santoni N. B., Melo T. G., Aguirre A. R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：AFATINIB与GEFITINIB的成本效果分析作为巴西私立医疗系统局部晚期或转移表皮生长因子受体突变阳性非小细胞肺癌患者的第一线治疗
3. COST-EFFECTIVENESS OF AFATINIB VERSUS PEMETREXED PLUS CISPLATIN AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EFGR) NON-SMALL CELL LUNG CANCER (NSCLC) IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM [J] . Santoni N. B., Melo T. G., Aguirre A. R., Value in health: the journal of the International Society for Pharmacoeconomics and Outcomes Research . 2017,第5期

机译：AFATINIB对巴西私人医疗系统中局部晚期或转移表皮生长因子受体突变阳性（EFGR）非小细胞肺癌（EFGR）的患者中的第一线治疗
4. Effect of preoperative cancer treatment on epidermal growth factor receptor (EGFR) receptor expression level in ABY-029 guided sarcoma surgery [C] . Xiaochun Xu, Kimberley S Samkoe, Eric R. Henderson Society of Photo-Optical Instrumentation Engineers;Conference on Molecular-Guided Surgery: Molecules, Devices, and Applications . 2020

机译：术前癌症治疗对ABY-029导向肉瘤手术中表皮生长因子受体（EGFR）受体表达水平的影响
5. Predictive Biomarkers of the Efficacy of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treating Advanced Non-small Cell Lung Cancer: A Systematic Review of Randomized Controlled Trials [D] . Yang, Zuyao. 2014

机译：表皮生长因子受体酪氨酸激酶抑制剂治疗晚期非小细胞肺癌疗效的预测生物标志物：随机对照试验的系统评价。
6. A Real-World Observational Prospective Study to Assess the Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations upon Progression on or after First-Line Therapy with a First- or Second-Generation EGFR Tyrosine Kinase Inhibitor in EGFR Mutation-Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer: The ‘LUNGFUL’ Study [O] . Giannis Mountzios, Anna Koumarianou, Alexandros Bokas, 2021

机译：真实世界观测性前瞻性研究以评估表皮生长因子受体（EGFR）突变的分子流行病学在一线治疗中或二进代EGFR酪氨酸激酶抑制剂在EGFR突变局部局部先进或转移性非小细胞肺癌：悠久的研究
7. MuTAR study, Phase II, open-label study of erlotinib (E) treatment in patients (pts) with locally advanced or metastatic non-small cell lung cancer (mNSCLC) who present activating mutations (MUT+) in the tyrosine kinase (TKI) domain of the epidermal growth factor receptor (EGFR), assessed the efficacy of 1L in Portuguese pts with mNSCLC EGFR Mut+ [O] . Barata F., Queiroga H., Teixeira E., 2016

机译：MuTAR研究，II期，开放标签研究厄洛替尼（E）治疗在局部晚期或转移性非小细胞肺癌（mNSCLC）患者中出现酪氨酸激酶（TKI）结构域激活突变（MUT +）的患者（pts）表皮生长因子受体（EGFR）的研究，通过mNSCLC EGFR Mut +评价了1L在葡萄牙患者中的疗效

COST-EFFECTIVENESS ANALYSIS OF AFATINIB VERSUS ERLOTINIB AS FIRST LINE TREATMENT IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC EPIDERMAL GROWTH FACTOR RECEPTOR MUTATION-POSITIVE (EGFR) NON-SMALL CELL LUNG CANCER IN THE BRAZILIAN PRIVATE HEALTHCARE SYSTEM

著录项

相似文献

相关主题

期刊订阅